MedTrace Logo

Slimming Myokines, Cancers,Nutritional and Psychology Support

NCT05278078 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2022-03-14

No results posted yet for this study

Summary

With the project investigators propose, investigators aim to find answers to the following questions: The fact that irisin and atropine are slimming the proteins that cause an increase in weight loss, and the excessive wasting (cachexia) in some types of cancer makes us wondering whether these factors may be cachectic factors for some GIS and US cancers? It is aimed to determine the relationship between irisin, atropine, some cachectic factors (PIF, ZAG), and cytokines (TNF-α, IL-1, IL-6) at tissue and plasma levels in these types of cancer. In addition, will psycho and nutrition education be applied to patients have an effect on cachexia? Experimental approaches to be used to find answers to such questions make this project unique.

Conditions

Interventions

OTHER

psychological support

psychological support will be given to the patients in the experimental group.

OTHER

nutritional education

nutritional education will be given to the patients in the experimental group.

OTHER

psychological support and nutritional education

psychological support and nutritional education will be given to the patients in the experimental group.

OTHER

no intervation

No intervention will be applied to the control group

Sponsors & Collaborators

  • T.C. ORDU ÜNİVERSİTESİ

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-08-01
Completion
2024-08-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05278078 on ClinicalTrials.gov